trending Market Intelligence /marketintelligence/en/news-insights/trending/1kJTUpUuQ3gKJbFk_ZHUdg2 content esgSubNav
In This List

Principia Biopharma director dies

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes


Principia Biopharma director dies

Principia Biopharma Inc. said one of its directors, Lewis Shuster, has died.

The South San Francisco, Calif.-based company also said it fell out of compliance with the Nasdaq's listing rules as Shuster's death reduced the members of Principia's audit committee to two. The stock market requires listed companies' audit committees to have at least three members.

Principia plans to regain compliance by appointing a new independent director, the company said in a filing.

Principia develops oral therapies for immunology and oncology in the U.S.